Abstract

ObjectiveIn ovarian cancer, two of the most important prognostic factors for survival are completeness of staging and completeness of cytoreductive surgery. Therefore, intra-operative visualization of tumor lesions is of great importance. Preclinical data already demonstrated tumor visualization in a mouse-model using near-infrared (NIR) fluorescence imaging and indocyanine green (ICG) as a result of enhanced permeability and retention (EPR). The aim of this study was to determine feasibility of intraoperative ovarian cancer metastases imaging using NIR fluorescence imaging and ICG in a clinical setting.MethodsTen patients suspected of ovarian cancer scheduled for staging or cytoreductive surgery were included. Patients received 20 mg ICG intravenously after opening the abdominal cavity. The mini-FLARE NIR fluorescence imaging system was used to detect NIR fluorescent lesions.Results6 out of 10 patients had malignant disease of the ovary or fallopian tube, of which 2 had metastatic disease outside the pelvis. Eight metastatic lesions were detected in these 2 patients, which were all NIR fluorescent. However, 13 non-malignant lesions were also NIR fluorescent, resulting in a false-positive rate of 62%. There was no significant difference in tumor-to-background ratio between malignant and benign lesions (2.0 vs 2.0; P=0.99).ConclusionsThis is the first clinical trial demonstrating intraoperative detection of ovarian cancer metastases using NIR fluorescence imaging and ICG. Despite detection of all malignant lesions, a high false-positive rate was observed. Therefore, NIR fluorescence imaging using ICG based on the EPR effect is not satisfactory for the detection of ovarian cancer metastases. The need for tumor-specific intraoperative agents remains.Trial RegistrationISRCTN Registry ISRCTN16945066

Highlights

  • Ovarian cancer has a worldwide incidence of 225,500 making it the 6th most common cancer in women

  • Eight metastatic lesions were detected in these 2 patients, which were all NIR fluorescent

  • This research was performed within the framework of CTMM, the Center for Translational Molecular Medicine; project MUSIS

Read more

Summary

Introduction

Ovarian cancer has a worldwide incidence of 225,500 making it the 6th most common cancer in women. Ovarian cancer can be classified as early stage (FIGO I to IIa) or advanced stage (FIGO IIb to IV). Stage ovarian cancer has a 5 year survival of 75–100%, with the most important factors influencing survival being differentiation grade of the tumor and the completeness of staging [1]. When no metastases are present, resection of the primary tumor is the treatment of choice and chemotherapy can be avoided [4]. Optimal staging has been shown to improve survival in low stage ovarian cancer because it discriminates true early stage ovarian cancer from occult tumor spread, which results in more advanced disease [4]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call